Loading…
Lyka Labs (LYKALABS)₹80.60+0.62%Pharmaceuticals
Lyka Labs is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a ROCE of −6.0% against a peer median of 12.0%, and latest-quarter sales growth of 20.6% against a peer median of 20.6%. By market cap it is #3 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Astonea Labs | 352 | 77.5 | 11.0 | 11.9 | 0.75 | 0.0 | 148 | 5 | — | — | vs LYKALABS |
| Aarey Drugs & Pharmaceuticals | 337 | 66.9 | 6.0 | 2.8 | 0.33 | 0.0 | 474 | 4 | 75.4 | 237.0 | vs LYKALABS |
| Lyka Labs | 292 | — | −6.0 | −10.2 | 0.53 | 0.0 | 128 | −10 | 20.6 | — | — |
| Ambalal Sarabhai Enterprises | 276 | 20.6 | 12.1 | 12.3 | 0.36 | 0.0 | 202 | 18 | 7.9 | −51.5 | vs LYKALABS |
| Astal Laboratories | 263 | 17.3 | 9.0 | 8.0 | 0.15 | 0.0 | 249 | 15 | — | — | vs LYKALABS |
| Everest Organics | 255 | 44.6 | 12.0 | 7.6 | 0.66 | 0.0 | 196 | 6 | 19.2 | −9.7 | vs LYKALABS |
| Sat Kartar Life | 245 | 14.2 | 36.0 | 26.5 | 0.04 | 0.5 | 201 | 17 | 26.7 | 28.4 | vs LYKALABS |
| BDH Industries | 240 | 22.1 | 19.9 | 14.8 | 0.03 | 1.2 | 96 | 11 | 62.8 | 15.6 | vs LYKALABS |
| Zenotech Laboratories | 238 | — | 4.6 | −1.2 | 0.00 | 0.0 | 44 | −1 | 10.2 | −145.0 | vs LYKALABS |
| Accretion Nutraveda | 237 | 47.2 | 27.8 | 25.1 | 0.12 | 0.0 | 34 | 5 | 80.4 | 56.1 | vs LYKALABS |
| Accretion Pharmaceuticals | 225 | 23.3 | 28.9 | 27.6 | 0.23 | 0.0 | 89 | 10 | 18.2 | 13.9 | vs LYKALABS |
| Peer median | 255 | 23.3 | 12.0 | 11.9 | 0.23 | 0.0 | 148 | 6 | 20.6 | 14.8 |
Listed companies closest to Lyka Labs in Pharmaceuticals include Astonea Labs, Aarey Drugs & Pharmaceuticals, Ambalal Sarabhai Enterprises, Astal Laboratories, Everest Organics, Sat Kartar Life, BDH Industries, Zenotech Laboratories.
Astonea Labs, with a market cap of ₹352 Cr.
Lyka Labs' return on capital employed is −6.0%, below the peer median of 12.0%.